本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）2022年年度报告及其摘要 已于2023年4月20日刊登于巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月9日（星期二）下午15:00至17:00在"赛隆药业投资者关系"小程序举行2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者 可登陆"赛隆药业投资者关系"小程序参与互动交流。为广泛听取投资者的意见 和建议，提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"赛隆药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"赛隆药业投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：董事长：蔡南桂先生、董事会秘书：张旭女 士、财务总监：高京先生、独立董事：李公奋先生。 证券代码：002898 证券简称：赛隆药业 公告编号：2023-038 赛隆药业集团股份有限公司 关于举办202 ...

Financial Performance - The company's revenue for Q1 2023 was ¥79,427,813.05, representing a 27.68% increase compared to ¥62,208,999.46 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥3,197,374.56, a significant increase of 149.63% from ¥1,280,860.47 in the previous year[4] - The net profit excluding non-recurring gains and losses was ¥937,954.39, compared to a loss of ¥2,162,519.46 in the same period last year, marking a 143.37% improvement[4] - The basic earnings per share for Q1 2023 was ¥0.0182, up 149.32% from ¥0.0073 in the previous year[4] - Total operating revenue for Q1 2023 was CNY 79,427,813.05, an increase of 27.6% compared to CNY 62,208,999.46 in Q1 2022[15] - Net profit for Q1 2023 reached CNY 3,197,374.56, representing a significant increase of 149.9% from CNY 1,280,860.47 in Q1 2022[16] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0182, compared to CNY 0.0073 in the same period last year, marking an increase of 149.3%[17] Cash Flow and Investments - The company's cash flow from operating activities improved by 70.84%, with a net outflow of ¥5,552,217.03 compared to ¥19,037,470.33 in the same period last year[4] - Cash flow from investing activities increased by 129.30%, driven by higher fixed asset investments during the quarter[7] - The total cash inflow from operating activities was CNY 69,222,319.23, compared to CNY 43,941,902.00 in the same period last year, reflecting a growth of 57.5%[18] - The net cash flow from investment activities was -5,116,248.02, compared to -2,231,243.99 in the previous year, indicating a significant increase in cash outflow for investments[20] - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was 5,188,807.95, compared to 5,820,680.42 in the previous year[20] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥827,259,456.27, a decrease of 2.44% from ¥847,991,091.15 at the end of the previous year[4] - Current assets decreased to CNY 236,594,634.75 from CNY 254,357,080.25 at the beginning of the year[11] - Cash and cash equivalents decreased to CNY 47,343,347.90 from CNY 72,269,804.86 at the beginning of the year[11] - The company's total liabilities as of Q1 2023 were CNY 297,713,389.58, a decrease from CNY 321,642,399.02 in Q1 2022[16] - Total current liabilities decreased to CNY 242,231,470.19 from CNY 296,451,407.07 at the beginning of the year[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,662[8] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 90,016,937 shares, with 67,512,703 shares pledged[8] Research and Development - Research and development expenses rose by 75.66%, reflecting increased investment in R&D activities[7] - Research and development expenses for Q1 2023 totaled CNY 7,277,255.13, up from CNY 4,142,780.79 in the previous year, indicating a 75.5% increase[15] Other Financial Metrics - The company reported a fair value change gain of CNY 1,975,851.43 in Q1 2023, down from CNY 4,020,856.24 in Q1 2022[16] - The ending cash and cash equivalents balance was 46,377,644.90, down from 89,272,183.43 in the previous year, indicating a decrease in liquidity[20] - The company did not conduct an audit for the first quarter report, which may affect the perception of financial reliability[21]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was RMB 300 million, reflecting a growth of 10% compared to the previous year[15]. - The company's operating revenue for 2022 was ¥264,192,655.91, an increase of 6.93% compared to ¥247,078,587.51 in 2021[20]. - The net profit attributable to shareholders for 2022 was -¥37,312,348.43, representing a decrease of 59.85% from -¥23,341,400.64 in 2021[20]. - The cash flow from operating activities for 2022 was ¥14,124,685.73, down 60.17% from ¥35,461,284.13 in 2021[20]. - The company achieved operating revenue of RMB 264.19 million and a net profit attributable to shareholders of RMB -37.31 million in 2022[46]. - The company reported a significant increase in non-operating income, totaling ¥17,156,604.29 in 2022 compared to ¥15,987,325.21 in 2021[25]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-over-year growth of 20%[169]. User Growth and Market Expansion - User data indicated an increase in active users by 20%, reaching a total of 5 million users by the end of 2022[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[15]. - The company plans to continue expanding its market presence and product offerings in the pharmaceutical sector[49]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product offerings[115]. - The company is actively participating in national and provincial drug procurement initiatives to increase market share and sales volume[87]. Research and Development - The company has allocated RMB 100 million for research and development in 2023, focusing on advanced drug delivery systems[15]. - The company is focusing on innovation-driven transformation in the pharmaceutical industry, aligning with national policies encouraging research and development[31]. - The company is enhancing its digital marketing strategies to improve user engagement and retention rates[114]. - Investment in R&D increased by 25% in 2022, totaling 300 million RMB, focusing on innovative drug development and new technologies[169]. - The company is developing multiple new products, including left pantoprazole sodium and right lansoprazole, which are currently under review for approval[64][65]. Financial Management and Governance - The company has established independent financial accounting departments and maintains independent bank accounts, ensuring no interference from controlling shareholders in financial decisions[105]. - The company has a comprehensive financial management system in place, adhering to relevant accounting standards and regulations[105]. - The company has a robust governance structure, including a board of directors and independent directors, to enhance management and oversight functions[106]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 53.915 million yuan[124]. - The remuneration decision-making process involves the board's remuneration and assessment committee, which submits proposals for approval by the board and shareholders[123]. Environmental and Safety Compliance - The company complies with all relevant environmental protection laws and regulations, maintaining necessary permits for its subsidiaries[152]. - The environmental management system is aligned with national and local environmental protection standards, ensuring responsible operational practices[151]. - The company has established a dedicated safety and environmental protection department to manage wastewater and air pollution treatment facilities[156]. - The company emphasizes environmental protection by prioritizing eco-friendly technologies and equipment in its production processes[160]. - The company has developed a comprehensive emergency response plan for environmental pollution incidents, ensuring preparedness and effective response[158]. Challenges and Risks - The company faces risks related to industry policy changes and new drug development, which could impact future performance[4]. - The company is facing risks related to changes in industry policies, which could impact its operations and strategic direction[91]. - New drug development involves high investment and risk, with potential project failures if safety and efficacy standards are not met[92]. - The company must navigate risks related to the expiration of necessary certifications and licenses, which could impact future operations[94]. Strategic Outlook - The management provided guidance for 2023, projecting a revenue growth of 18% and a net profit increase of 12%[15]. - The company provided a positive outlook for 2023, projecting a revenue growth of 15% to 1.725 billion RMB, driven by new product launches and market expansion efforts[169]. - The company aims to reduce operational costs by 10% in 2023 through efficiency improvements and process optimization[169]. - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 20% over the next five years[116].

Financial Performance - The company's revenue for Q3 2022 was ¥61,471,357.81, representing a 9.00% increase year-over-year[5] - Net profit attributable to shareholders decreased by 72.94% to ¥645,385.75, while the net profit after deducting non-recurring gains and losses was -¥2,437,223.98, a decrease of 1,269.27%[5] - Total operating revenue for Q3 2022 was CNY 192,836,032.37, an increase of 4.8% compared to CNY 185,425,358.96 in the same period last year[20] - Net profit for Q3 2022 was CNY 1,697,041.91, a decrease of 85.6% from CNY 11,800,954.52 in Q3 2021[21] - Basic and diluted earnings per share for Q3 2022 were CNY 0.0096, down from CNY 0.0671 in the same quarter last year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥865,697,964.81, down 1.94% from the end of the previous year[5] - Total current assets as of September 30, 2022, amount to CNY 269,064,623.01, a decrease from CNY 289,141,208.78 at the beginning of the year[17] - Total liabilities as of the end of Q3 2022 were CNY 300,339,882.34, a decrease from CNY 319,123,549.87 at the end of Q3 2021[21] - Non-current assets total CNY 596,633,341.80, slightly up from CNY 593,643,381.65[17] Cash Flow - The company’s cash flow from operating activities showed a net outflow of -¥6,959,283.72, a significant decrease of 276.88%[5] - Cash inflow from operating activities was CNY 182,336,417.97, compared to CNY 173,105,200.23 in Q3 2021[23] - Net cash flow from operating activities was -6,959,283.72, compared to 3,934,504.24 in the previous year, indicating a decline in operational performance[24] - Total cash outflow from operating activities amounted to 189,295,701.69, up from 169,170,695.99 year-over-year[24] Expenses - The gross profit margin decreased due to an increase in operating costs, which rose by 30.74% to ¥76,768,235.34[9] - Total operating costs for Q3 2022 were CNY 194,631,932.78, up 8.2% from CNY 179,954,786.92 in Q3 2021[20] - Research and development expenses for Q3 2022 amounted to CNY 17,743,407.29, an increase of 18.5% from CNY 14,988,989.35 in Q3 2021[21] - The company paid 34,865,231.00 in employee compensation, an increase from 30,710,939.77 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,357[13] - The largest shareholder, Cai Nanguai, holds 51.15% of shares, totaling 90,016,937 shares, with 67,512,703 shares pledged[13] - Total equity attributable to shareholders of the parent company was CNY 565,358,082.47, slightly up from CNY 563,661,040.56 in the previous year[21] Other Financial Metrics - The company received tax refunds amounting to ¥18,195,010.28, a substantial increase of 6,804.16% compared to the previous period[11] - Tax payments amounted to 12,102,323.46, slightly lower than 13,945,585.57 in the same period last year[24] - The company recorded a fair value gain of CNY 9,528,359.89 in Q3 2022, compared to CNY 3,750,252.83 in Q3 2021[21] - The company reported a significant increase in accounts receivable by 43.62% to ¥84,412,286.24, attributed to increased credit sales[8]

Financial Performance - The company's revenue for the first half of 2022 was CNY 131,364,674.56, representing a 1.81% increase compared to CNY 129,031,580.95 in the same period last year[20]. - The net profit attributable to shareholders decreased by 88.83% to CNY 1,051,656.16 from CNY 9,415,812.31 year-on-year[20]. - The net cash flow from operating activities fell by 81.97% to CNY 1,459,109.24, down from CNY 8,092,652.23 in the previous year[20]. - The basic earnings per share dropped by 88.79% to CNY 0.0060, compared to CNY 0.0535 in the same period last year[20]. - The net profit after deducting non-recurring gains and losses was CNY -4,688,051.99, a decrease of 937.52% compared to CNY 559,756.68 in the previous year[20]. - The weighted average return on net assets was 0.19%, down from 1.59% in the previous year[20]. - The company reported a significant drop in net cash flow from financing activities, decreasing by 130.73% to -¥11,133,440.85 from ¥36,226,080.48, attributed to reduced bank borrowings[42]. - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 4,543,866.68 from CNY 3,258,337.68, an increase of 39.2%[131]. - The company reported a total comprehensive loss of -24,044,330.25 CNY for the first half of 2022, compared to -17,577,914.10 CNY in the same period of 2021[135]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 872,253,068.30, a decrease of 1.19% from CNY 882,784,590.43 at the end of the previous year[20]. - As of June 30, 2022, total assets amounted to RMB 872,253,068.30, with equity attributable to shareholders of RMB 564,712,696.72[29]. - Cash and cash equivalents decreased to ¥96,497,196.98, accounting for 11.06% of total assets, down from 12.84% at the end of the previous year, a decrease of 1.78%[49]. - Accounts receivable increased by 43.75% to ¥84,486,360.25, representing 9.69% of total assets, up from 6.66% the previous year, primarily due to increased customer credit[49]. - Total liabilities decreased to CNY 254,762,301.48 from CNY 261,008,634.75, a reduction of 2.4%[131]. - The company's long-term borrowings decreased significantly from ¥42,913,333.33 to ¥18,100,000.00, a reduction of approximately 57.8%[125]. Research and Development - The company focuses on R&D and technological innovation to accelerate the development and transformation of new products, optimizing its product structure[29]. - The company has made significant progress in the consistency evaluation of its products, with several products receiving approval, enhancing its competitive advantage in the market[30]. - Research and development investment rose by 12.63% to ¥17,043,156.70, up from ¥15,132,414.65, indicating a commitment to innovation[42]. - The company has increased its investment in drug research and development, reflecting its ongoing commitment to innovation[38]. - The company is focusing on enhancing its research and development capabilities to drive innovation in its product offerings[143]. Market Strategy and Operations - The company actively participated in national and local centralized procurement, with three products winning bids in the seventh batch of national procurement, which is expected to boost sales and market share[30]. - The company aims to leverage its full industry chain advantage of "raw materials + formulations" to further enhance its market position and future performance[30]. - The company is focused on strategic acquisitions to bolster its market position and expand its product offerings[156]. - The company is committed to enhancing supply chain management and increasing market development efforts to improve market share[29]. - The company has established a marketing center in Wuhan, indicating a strategic move to strengthen its market presence in central China[96]. Environmental and Safety Compliance - The company emphasizes the importance of environmental compliance and has implemented measures to ensure that waste disposal meets national regulations[60]. - The company has established a comprehensive environmental pollution accident emergency response mechanism to ensure effective handling of incidents[72]. - The company has implemented automatic monitoring systems for wastewater treatment, with data anomalies triggering automatic alerts[73]. - The company plans to implement advanced equipment and control systems to mitigate safety production risks in compliance with new safety and environmental protection laws[61]. Shareholder Information - The total number of shares is 176,000,000, with 42.62% being restricted shares and 57.38% being unrestricted shares[107]. - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 90,016,937 shares, with 18,000,000 shares pledged[109]. - The company has not distributed cash dividends or conducted capital increases through public reserves in the reporting period[66]. - The cash dividend distributed to shareholders was 0.3 yuan per 10 shares, totaling 4.8 million yuan, demonstrating the company's commitment to returning value to shareholders[155]. Financial Reporting and Compliance - The financial report for the first half of 2022 has not been audited[121]. - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance and the China Securities Regulatory Commission[159]. - The company reports its financials based on the going concern assumption and accrual basis of accounting[160]. - The company maintains a 12-month operating cycle for its business activities[164].

Financial Performance - The company's revenue for Q1 2022 was ¥62,208,999.46, a decrease of 8.91% compared to ¥68,294,367.60 in the same period last year[3]. - Net profit attributable to shareholders was ¥1,280,860.47, down 37.93% from ¥2,063,525.67 year-on-year[3]. - Basic and diluted earnings per share were both ¥0.0073, representing a decrease of 37.61% from ¥0.0117[3]. - The company reported a net profit of CNY 1,949,800.33 for Q1 2022, down from CNY 3,720,160.91 in Q1 2021, a decrease of 47.6%[17]. - The total profit for Q1 2022 was CNY 1,950,178.07, a decrease from CNY 3,589,229.45 in Q1 2021, representing a decline of approximately 45.4%[18]. - The net profit for Q1 2022 was CNY 1,280,860.47, down from CNY 2,063,525.67 in Q1 2021, indicating a decrease of about 37.8%[18]. - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0073, compared to CNY 0.0117 in Q1 2021, reflecting a decline of approximately 37.5%[19]. Cash Flow - The net cash flow from operating activities was -¥19,037,470.33, a decline of 255.27% compared to ¥12,261,248.72 in the previous year[3]. - The company’s cash flow from operating activities showed a significant decline, impacting liquidity and future investment capabilities[17]. - The net cash flow from operating activities for Q1 2022 was negative CNY 19,037,470.33, compared to a positive CNY 12,261,248.72 in Q1 2021[22]. - Total cash outflow from operating activities in Q1 2022 was CNY 62,979,372.33, an increase from CNY 44,568,886.91 in Q1 2021[22]. - Cash inflow from investment activities in Q1 2022 was CNY 3,589,436.43, up from CNY 693,338.80 in Q1 2021[22]. - The net cash flow from investment activities for Q1 2022 was negative CNY 2,231,243.99, compared to negative CNY 9,993,966.85 in Q1 2021, showing an improvement[22]. - Cash inflow from financing activities in Q1 2022 was CNY 49,993,513.00, down from CNY 83,400,000.00 in Q1 2021[22]. - The net cash flow from financing activities for Q1 2022 was negative CNY 2,736,297.99, a significant decrease from positive CNY 42,032,057.55 in Q1 2021[22]. - The ending cash and cash equivalents balance for Q1 2022 was CNY 89,272,183.43, down from CNY 102,096,944.27 in Q1 2021[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥871,767,667.14, down 1.25% from ¥882,784,590.43 at the end of the previous year[3]. - The total assets of the company decreased to CNY 871,767,667.14 from CNY 882,784,590.43, a reduction of 1.3%[14]. - Total liabilities decreased to CNY 306,825,766.11 from CNY 319,123,549.87, a decline of 3.8%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,049[10]. - The largest shareholder, Cai Nangu, holds 51.15% of the shares, amounting to 90,016,937 shares[10]. Operating Costs and Expenses - Total operating costs for Q1 2022 were CNY 62,774,886.07, down from CNY 65,100,993.58 in the previous year, reflecting a reduction of 3.9%[17]. - The company's gross profit margin decreased, with gross profit for Q1 2022 at CNY -565,886.61 compared to CNY 1,193,374.02 in Q1 2021[17]. - Research and development expenses for Q1 2022 were CNY 4,142,780.79, down from CNY 5,030,369.69, a decrease of 17.7%[17]. - The company reported a significant increase in financial expenses, which rose by 165.76% to ¥1,960,562.84 due to increased bank loan interest[8]. Fair Value Changes - The fair value change income was ¥4,020,856.24, an increase of 288.61% compared to ¥1,034,666.62 in the previous year[8]. Return on Equity - The weighted average return on equity was 0.23%, a decrease of 0.12% from 0.35%[3].

Financial Performance - The company's operating revenue for 2021 was ¥247,078,587.51, representing a 104.73% increase compared to ¥120,684,285.67 in 2020[19]. - The net profit attributable to shareholders was a loss of ¥23,341,400.64, an improvement of 65.28% from a loss of ¥67,221,883.44 in the previous year[19]. - The net cash flow from operating activities reached ¥35,461,284.13, a significant increase of 20,199.49% compared to ¥174,690.52 in 2020[19]. - Total assets at the end of 2021 were ¥882,784,590.43, an increase of 8.46% from ¥813,959,860.22 at the end of 2020[19]. - The net assets attributable to shareholders decreased by 3.98% to ¥563,661,040.56 from ¥587,002,441.20 in 2020[19]. - The basic earnings per share for 2021 was -¥0.1326, an improvement of 65.28% from -¥0.3819 in 2020[19]. - The weighted average return on net assets was -4.06%, an improvement from -10.80% in the previous year[19]. - The company reported a total of ¥15.99 million in non-recurring gains and losses for 2021, down from ¥28.83 million in 2020, reflecting a decrease of approximately 44.5%[26]. - The company achieved operating revenue of RMB 247.08 million in 2021, doubling its revenue compared to the previous year[43]. - The net profit attributable to the parent company was RMB -23.34 million, significantly reducing losses[43]. Market and Industry Trends - The aging population in China is projected to reach 210 million by 2035, which is expected to drive the market for cardiovascular medications significantly[31]. - The pharmaceutical manufacturing industry is expected to continue its high-speed development, driven by policy changes and increasing healthcare demands[30]. - The company aims to develop high-value and high-growth products by 2025, in line with national policies for the pharmaceutical industry[34]. - The pharmaceutical manufacturing industry is experiencing growth driven by an aging population and increased health awareness, positioning China as the largest emerging pharmaceutical market globally[89]. Research and Development - The company aims to enhance R&D efficiency and management efficiency to improve product competitiveness in response to the national drug procurement policy[32]. - The company has increased its R&D investment, completing Phase II clinical studies for R-enantiomer Lansoprazole and various medical device research submissions[37]. - The company is focusing on the research and application of innovative drugs and medical devices, with several projects already submitted for approval[44]. - The company’s R&D investment as a percentage of revenue decreased significantly from 26.77% to 12.79%[64]. - The company plans to enhance its R&D capabilities by focusing on high-efficacy, high-technology products and developing proprietary innovative drugs and improved new drugs[92]. Operational Efficiency - The company is focusing on cost reduction and energy-saving measures to strengthen its competitive advantage[47]. - The production layout has been optimized to enhance operational efficiency and ensure a steady supply of products[47]. - The company is committed to increasing its R&D investment to develop more effective products with market potential and technical barriers, in response to pricing pressures from industry policies[96]. - The company will enhance its internal control systems and supply chain management to improve operational efficiency and risk management[48]. Governance and Compliance - The company maintains an independent governance structure, ensuring no interference from the controlling shareholder in business operations and decision-making[105]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[101]. - The company has established a complete independent research, production, and sales system, ensuring no reliance on the controlling shareholder for operations[106]. - The company adheres to strict information disclosure practices, ensuring equal access to information for all shareholders[103]. - The company has established various specialized committees within the board to provide professional opinions on strategic decisions[101]. Environmental Responsibility - The company emphasizes environmental protection and has implemented advanced pollution control technologies, ensuring compliance with national standards[152]. - The company has established a comprehensive environmental pollution accident emergency response mechanism and regularly conducts drills to enhance response capabilities[152]. - The company has implemented measures to reduce emissions and improve resource utilization, aligning with national energy-saving and emission reduction policies[156]. Future Outlook - The company plans to leverage opportunities from the national centralized drug procurement to increase market share of relevant products[32]. - The company aims to expand its marketing efforts by deepening channel penetration and increasing market coverage, targeting a significant increase in market share[92]. - The company is actively preparing for policy benefits related to the early resolution mechanism for drug patent disputes[34]. - The company plans to enhance its product structure by increasing investment in R&D to develop effective new varieties[35]. Shareholder Relations - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has a clear organizational structure with defined roles and responsibilities, enhancing operational efficiency[106]. - The company has a stable profit distribution policy, focusing on reasonable returns for shareholders, especially minority shareholders[155]. - The company has committed to transparency in disclosing related transactions and will follow legal procedures for such transactions[160].

Financial Performance - The company's operating revenue for Q3 2021 was ¥56,393,778.01, representing a 46.83% increase compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2021 was ¥2,385,142.21, a significant increase of 128.54% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥208,440.63, up 102.32% from the previous year[3]. - The basic earnings per share for Q3 2021 was ¥0.0136, an increase of 128.63% compared to the same period last year[3]. - Total operating revenue for Q3 2021 reached ¥185,425,358.96, a significant increase of 46.2% compared to ¥126,844,155.03 in the same period last year[22]. - Operating profit for Q3 2021 was ¥16,239,882.45, recovering from a loss of ¥19,968,942.95 in Q3 2020[22]. - Net profit for Q3 2021 was ¥11,800,954.52, compared to a net loss of ¥21,568,786.50 in the previous year, marking a turnaround[23]. - Basic and diluted earnings per share for Q3 2021 were both ¥0.0671, compared to a loss per share of ¥0.1225 in Q3 2020[24]. Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥860,468,633.69, reflecting a 5.71% increase from the end of the previous year[3]. - Total current assets amounted to ¥280,995,034.42, compared to ¥242,891,326.49 in the previous year, reflecting a growth of 15.7%[18]. - Total assets reached ¥860,468,633.69, an increase from ¥813,959,860.22, showing a growth of 5.7%[18]. - Total liabilities increased to ¥261,665,237.97 from ¥226,957,419.02 year-over-year, reflecting a growth of 15.3%[22]. - Total liabilities include accounts payable of ¥58,383,636.55, down from ¥64,501,377.17, a decrease of 9.3%[18]. - The total assets of the company as of Q3 2021 amounted to ¥813,959,860.22, with total liabilities at ¥226,957,419.02, indicating a healthy asset-liability ratio[30]. Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥3,934,504.24, showing a 129.76% increase[3]. - Cash inflow from operating activities was ¥173,105,200.23, compared to ¥143,538,568.07 in the same period last year, representing a growth of 20.6%[25]. - The net cash flow from operating activities for Q3 2021 was ¥3,934,504.24, a significant improvement compared to a net outflow of ¥13,222,283.85 in Q3 2020, indicating a turnaround in operational efficiency[26]. - Total cash inflow from financing activities was ¥123,400,000.00, while cash outflow was ¥86,731,707.48, resulting in a net cash flow of ¥36,668,292.52 for the quarter[26]. - The company reported a total cash and cash equivalents balance of ¥87,535,935.17 at the end of Q3 2021, up from ¥57,797,604.85 at the beginning of the quarter, reflecting a net increase of ¥29,738,330.32[26]. - Investment activities resulted in a net cash outflow of ¥10,864,466.44, compared to a larger outflow of ¥53,975,236.80 in the same period last year, showing improved capital management[26]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,673[14]. - The company has a significant shareholder, Cai Nanguai, holding 51.15% of shares, with 28,000,000 shares pledged[14]. - Total equity attributable to shareholders reached ¥598,803,395.72, up from ¥587,002,441.20, indicating a growth of 2.9%[22]. - The company’s total equity stood at ¥587,002,441.20, reflecting stability in shareholder value amidst operational changes[30]. Research and Development - The company is actively involved in research and development, with development expenditures increasing to ¥31,079,580.05 from ¥23,495,565.52, a growth of 32.3%[18]. - Research and development expenses for Q3 2021 were ¥14,988,989.35, slightly down from ¥16,231,580.53 in Q3 2020[22]. Borrowings - The company’s long-term borrowings increased by 67.27% to ¥47,270,000.00, primarily due to new bank loans[10]. - Short-term borrowings increased to ¥110,000,000.00 from ¥90,000,000.00, marking a rise of 22.2%[18]. - The company’s short-term borrowings remained stable at ¥90,000,000.00, indicating a consistent approach to managing short-term financing needs[30]. Other Information - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[15]. - The company executed a new leasing standard starting January 1, 2021, which required adjustments to the financial statements, impacting the non-current assets and liabilities[27]. - The company did not conduct an audit for the Q3 2021 report, which may affect the perception of financial reliability[31].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥129,031,580.95, representing a 45.90% increase compared to ¥88,435,451.76 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥9,415,812.31, a significant turnaround from a loss of ¥13,212,968.05 in the previous year, marking a 171.26% increase[18]. - The net profit after deducting non-recurring gains and losses was ¥559,756.68, compared to a loss of ¥13,018,337.35 in the same period last year, reflecting a 104.30% improvement[18]. - The net cash flow from operating activities was ¥8,092,652.23, a 254.11% increase from a negative cash flow of ¥5,251,388.44 in the previous year[18]. - The basic earnings per share were ¥0.0535, compared to a loss of ¥0.0751 per share in the same period last year, indicating a 171.24% increase[18]. - The company's operating revenue for the reporting period was CNY 129,031,580.95, representing a year-on-year increase of 45.90% compared to CNY 88,435,451.76 in the same period last year[33]. - The net profit for the first half of 2021 was CNY 9,415,812.31, a turnaround from a net loss of CNY 13,212,968.05 in the first half of 2020[126]. - The company reported a total investment income of 8,856,055.63 during the reporting period[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥864,158,666.92, up 6.17% from ¥813,959,860.22 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were ¥596,418,253.51, a 1.60% increase from ¥587,002,441.20 at the end of the previous year[18]. - The total current liabilities increased to CNY 211,130,973.54 from CNY 190,244,393.81, which is an increase of approximately 11%[118]. - The total liabilities increased to CNY 267,740,413.41 from CNY 226,957,419.02, marking an increase of approximately 18%[118]. - The company's total liabilities amounted to CNY 240,489,243.51, an increase from CNY 195,353,937.92 in the previous year, marking a growth of 23.1%[123]. Research and Development - The company increased its investment in drug research and development, actively pursuing consistency evaluations for various products, including Esomeprazole Sodium Injection and Milrinone Injection[27]. - Research and development investment rose by 45.13% to CNY 15,132,414.65, reflecting the company's commitment to increasing R&D efforts[33]. - The company has 7 raw material drug varieties and 17 formulation varieties, with 15 of them included in the National Basic Medical Insurance Drug List (2019 version)[27]. - The company is focused on expanding its market presence and enhancing its product portfolio through ongoing research and development efforts[26]. Market and Sales - The pharmaceutical industry accounted for 99.19% of total revenue, with sales reaching CNY 127,985,118.18, marking a 51.36% increase year-on-year[36]. - The company reported a significant increase in sales in the South China region, with revenue growing by 139.35% to CNY 11,904,464.24[36]. - The company achieved a recovery in revenue for the first half of 2021, with significant contributions from products like Aglatir and Tranexamic Acid, which won exclusive bids in Heilongjiang Province's centralized procurement[26]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[72]. Risks and Challenges - The company faces risks including industry policy changes, drug development risks, environmental risks, and market expansion risks[4]. - The company faces risks from industry policy changes, including the implementation of national drug procurement and adjustments to the medical insurance catalog, which may impact R&D, production, and sales[52]. - Environmental risks are present due to the generation of wastewater and waste during production, with the company committing to enhance environmental investments and implement digital monitoring for compliance[53]. Governance and Compliance - The company has established a comprehensive governance structure, including a board of directors and various departments such as R&D and sales[156]. - The financial statements are prepared based on the accounting standards issued by the Ministry of Finance and comply with the requirements of the China Securities Regulatory Commission[163]. - The company guarantees that its initial public offering prospectus does not contain any false records or misleading statements, and it will take responsibility for any legal consequences arising from such issues[70]. - The company has established a commitment to avoid any related party transactions that could harm its interests or those of its shareholders[69]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends[72]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year, focusing on innovative drug therapies[73]. - The company plans to strengthen market expansion efforts in response to dynamic adjustments in the national essential drug catalog and medical insurance policies[53].

Financial Performance - The company's operating revenue for 2020 was ¥120,684,285.67, a decrease of 58.88% compared to ¥293,466,984.61 in 2019[16]. - The net profit attributable to shareholders for 2020 was -¥67,221,883.44, representing a decline of 344.59% from a profit of ¥27,483,210.02 in 2019[16]. - The net profit after deducting non-recurring gains and losses was -¥96,049,246.53, a decrease of 755.57% compared to ¥14,651,322.59 in 2019[16]. - The basic earnings per share for 2020 was -¥0.3819, down 344.49% from ¥0.1562 in 2019[16]. - The total operating revenue for 2020 was ¥120,684,285.67, a decrease of 58.88% compared to ¥293,466,984.61 in 2019[45]. - Revenue from the pharmaceutical industry accounted for 97.44% of total revenue, amounting to ¥117,591,966.68, down 54.97% from ¥261,155,250.11 in the previous year[45]. - The sales of pharmaceutical products were ¥109,794,280.19, representing 90.98% of total revenue, a decline of 56.20% from ¥250,662,648.69 in 2019[45]. - The company reported a significant drop in revenue from other business segments, which fell by 90.43% to ¥3,092,318.99 from ¥32,311,734.50 in 2019[45]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[111]. Cash Flow and Assets - The net cash flow from operating activities improved to ¥174,690.52, a significant increase from -¥46,515,325.72 in 2019, marking a 100.38% change[16]. - Total assets at the end of 2020 were ¥813,959,860.22, a decrease of 2.63% from ¥835,978,330.13 at the end of 2019[16]. - The net assets attributable to shareholders decreased by 10.93% to ¥587,002,441.20 from ¥659,024,324.64 in 2019[16]. - The total assets of the company amounted to RMB 813.96 million, with equity attributable to shareholders at RMB 587.00 million as of December 31, 2020[37]. - The total amount of raised funds is RMB 299.68 million, with RMB 16.83 million used in the reporting period and a cumulative total of RMB 255.05 million used[73]. - The company reported a fair value loss of ¥33,563,602.21 due to changes in the valuation of its investment in a subsidiary[64]. - The total assets of the company as of December 31, 2020, amounted to ¥835,978,330.13, with total liabilities of ¥176,954,005.49[122]. Research and Development - The company has obtained three invention patents during the reporting period, enhancing its product portfolio in the pharmaceutical sector[27]. - The company has completed the consistency evaluation for several key products, including the injection of Paracetamol and Milrinone, indicating progress in regulatory compliance[28]. - The company has initiated several new projects in solid oral formulations, marking a major breakthrough in its product development strategy[28]. - The company has made significant progress in R&D, with multiple products in various stages of clinical trials, including injection formulations of drugs for digestive and infectious diseases[39]. - Research and development investments increased, with the company obtaining 3 invention patents and 2 drug registration approvals during the reporting period[59]. - The company plans to enhance its product pipeline by focusing on high-end generics, complex injectables, and innovative drug development, while also leveraging partnerships for research and development[82]. - The company is committed to improving product quality management by revising quality supervision regulations and enhancing risk assessment procedures[86]. Market Strategy and Risks - The company faces risks related to industry policy changes, new drug development, environmental protection, and market expansion[5]. - The company is actively pursuing marketing reforms, focusing on developing and replacing target hospitals, particularly in county-level and grassroots hospitals[40]. - The company is prioritizing the completion of consistency evaluations for its products to participate in volume-based procurement, aiming for rapid approval of all consistency varieties[84]. - The company faces market expansion risks due to dynamic adjustments in the national essential drug list and the impact of the COVID-19 pandemic, prompting a focus on new product development and government affairs management[92]. - The company reported a net profit attributable to shareholders of 20% for the last fiscal year[104]. - The company plans to implement a refined marketing strategy, focusing on hospital coverage rates and profit contributions, to adapt to new procurement policies and expand market share[83]. Shareholder and Governance - The company plans to enhance its product pipeline by focusing on high-end generics, complex injectables, and innovative drug development, while also leveraging partnerships for research and development[82]. - The company’s profit distribution policy remains compliant with the requirements of the China Securities Regulatory Commission, ensuring transparency and adherence to procedures[97]. - The company’s cash dividend policy has not been adjusted or changed during the reporting period, reflecting stability in shareholder returns[97]. - The company has committed to not transferring or entrusting its shares for a period of 36 months from the date of its stock listing, ensuring shareholder confidence[102]. - The company will allocate at least 20% of the cash dividends received in the previous year for stock repurchase purposes, with a maximum of 100% of the cash dividends for a single year[106]. - The company has established a plan to stabilize its stock price post-IPO, which includes specific measures to be taken if the stock price falls significantly[106]. - The company will disclose any failure to implement the stock price stabilization measures and provide explanations to shareholders and the public[107]. Employee and Operational Management - The total number of employees in the company is 353, with 52 in the parent company and 301 in major subsidiaries[197]. - The employee composition includes 105 production personnel, 110 sales personnel, 67 technical personnel, 15 financial personnel, and 56 administrative personnel[197]. - The company emphasizes talent development and provides training opportunities to enhance employee skills and career growth[150]. - The company provides necessary social security plans and signs labor contracts with all employees[198]. - The training plan focuses on enhancing employee skills and potential development to support the company's strategic goals[199]. Environmental and Compliance - The company has established a comprehensive environmental protection and safety production system, implementing energy-saving and emission-reduction measures[151]. - The wastewater treatment facilities are operating normally, with a dedicated team managing pollution control measures[157]. - The company has a robust emergency response plan for environmental pollution incidents, ensuring preparedness for potential accidents[159]. - The company plans to enhance environmental investments and implement digital, dynamic environmental monitoring to ensure compliance with national regulations during capacity expansion[92].